Home  >  News
  Study suggests combo therapy may prevent stroke in certain people,   May 19, 2018
  Pivot Pharma speeds up development of CBD products for domestic pet market,   May 19, 2018
  Aegea Biotechnologies' next generation nucleic acid clinical diagnostic technologies gets US, Australian & Chinese patents,   May 19, 2018
  Inovio Pharma to present phase 1b trial data of cancer immunotherapy, INO-5150 at ASCO 2018,   May 19, 2018
  CPhI & P-MEC China to take place at SNIEC from June 20-22,   May 19, 2018
  Oncolytics collaborates with Merck & Northwestern University to begin phase 2 study of Reolysin in combo with Keytruda to treat second line pancreatic cancer,   May 19, 2018
  NIH funded study shows male depression may lower pregnancy chances among infertile couples,   May 19, 2018
  Indoco‚Äôs Patalganga & Rabale API mfg. facilities successfully clear US FDA inspection,   May 19, 2018
  Boehringer Ingelheim supports collaboration and knowledge sharing in livestock industry,   May 19, 2018
  Amgen's Aimovig receives US FDA approval for preventive treatment of migraine in adults,   May 19, 2018
  Pfizer phase 3 study of Lyrica oral solution CV in paediatric epilepsy meets primary endpoint,   May 19, 2018
  Correvio's partner Eddingpharm begins patient enrollment in phase 3 study evaluating Brinavess in China,   May 18, 2018
  Strides Shasun incurs consolidated net loss of Rs.4 crore in Q4, scrip declines by over 23%,   May 18, 2018
  NIH funds 3 national cryo-EM service centers & training for new microscopists,   May 18, 2018
  Biocon sales 1.88 % stake in Syngene International,   May 18, 2018
  Innovent reports study result from ORIENT-1 trial of anti-PD-1 antibody, sintilimab in Hodgkin lymphoma,   May 18, 2018
  Taro Pharma's net sales dips by 11% in Q4 to US$175 million,   May 18, 2018
  Ipsen receives European approval for Cabometyx to treat adults with intermediate/poor-risk advanced RCC,   May 18, 2018
  Rousselot introduces new medical grade gelatin range, X-Pure,   May 18, 2018
  Glenmark presents phase 2a study of GBR 830, an anti-OX40 monoclonal antibody at IID meeting in Orlando,   May 18, 2018

cphikorea_150x60_saffron media
Copyright © 2016 Saffron Media Pvt. Ltd |